Clinical Data

chasing running uphill behind leadership climbing
Biotech

Novo's triple-G prospect passes midphase diabetes test in China

While the data suggest the asset is competitive, Eli Lilly’s head start in the space means it remains the company to beat.
Nick Paul Taylor Mar 25, 2026 4:30am
Close up of amber eye

Ocugen eye disease gene therapy nabs underwhelming ph. 2 win

Mar 24, 2026 10:40am
Closeup of blue eye on black background

Innovent eyes China approval after matching Eylea in phase 3

Mar 24, 2026 6:00am
target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am
lyme disease tick forest

Pfizer, Valneva miss Lyme shot ph. 3 goal but plan approval push

Mar 23, 2026 6:45am
Stop sign and red lights at traffic intersection

Genentech shreds RIPK1 inhibitor after ph. 2 failure

Mar 19, 2026 2:48pm